BioSpace News Archive

Cardiawave Confirms the Safety of VALVOSOFT ® its Non-Invasive Ultrasound Treatment for Aortic Stenosis.

Proscia® , a leader in digital and computational pathology solutions, has raised $37 million to advance the way we understand and treat diseases like cancer.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences.

ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing that the Company’s lead product candidate, exebacase was effective in a rabbit model of implant-associated osteomyelitis.

GenTegra Announces the Launch of RNAdvantage™ for Stabilization of RNA in Fresh Tissue Samples.

Experienced pharmaceutical development executive brings track record of advancing preclinical and clinical programs and successful commercial product launches.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced the appointment of Launa J. Aspeslet, PhD, RAC, as Chief Operating Officer.

Remington Medical, a medical device manufacturing company based in the U.S., announced the launch of VascuChek®, the industry’s first modern wireless, handheld vascular Doppler device for surgical and clinical use.

Rady Children’s Institute for Genomic Medicine announced a novel program to advance and evaluate scalability of a diagnostic and precision medicine guidance tool called BeginNGS™ to screen newborns for approximately 400 genetic diseases that have known treatment options using rapid Whole Genome Sequencing.

Silcock Brings Proven Experience in Transformational Growth to the Neptune Team.